Clinical trial · Observational
Introduction and Influence of Total Mesorectal Excision (TME) in the Treatment of Rectal Cancer
Introduction of Total Mesorectal Excision (TME) in the Treatment of Rectal Cancer. Influence of This New Operation Technique on Local Recurrence and Long-Time Survival. Retrospective Study: 1993-2001
NCT00910143CI-TRIAL-00002336completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Total mesorectal excision (TME) is a rather new operation technique in the treatment of rectal cancer. It is known to reduce the rate of local recurrences. However, the influence on long-term survival is unclear.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Rectal Cancer | Malignant Rectal Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| conventional rectal surgery | Procedure | — | UNRESOLVED |
| total mesorectal excision | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- 1
- description
- patients operated before summer 1995, that is before the introduction of TME
- interventionNames
- Procedure: conventional rectal surgery
- label
- 2
- description
- patients operated after summer 1995, that is after the introduction of TME.
- interventionNames
- Procedure: total mesorectal excision
Primary outcomes (1)
- measure
- Local recurrence, recurrence-free survival, overall survival
- timeFrame
- 6 months and 1, 2, 3, 4 and 5 years after the operation
Secondary outcomes (3)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 16 Years
Show eligibility criteria text
Inclusion Criteria: * adenocarcinoma of the rectum * 16 years and older
References
Publications (8)
- BACKGROUNDHeald RJ. Total mesorectal excision is optimal surgery for rectal cancer: a Scandinavian consensus. Br J Surg. 1995 Oct;82(10):1297-9. doi: 10.1002/bjs.1800821002. No abstract available. PMID 7489148
- BACKGROUNDMella J, Biffin A, Radcliffe AG, Stamatakis JD, Steele RJ. Population-based audit of colorectal cancer management in two UK health regions. Colorectal Cancer Working Group, Royal College of Surgeons of England Clinical Epidemiology and Audit Unit. Br J Surg. 1997 Dec;84(12):1731-6. PMID 9448628
- BACKGROUNDHeald RJ, Husband EM, Ryall RD. The mesorectum in rectal cancer surgery--the clue to pelvic recurrence? Br J Surg. 1982 Oct;69(10):613-6. doi: 10.1002/bjs.1800691019. PMID 6751457
- BACKGROUNDMaurer CA, Renzulli P, Meyer JD, Buchler MW. [Rectal carcinoma. Optimizing therapy by partial or total mesorectum removal]. Zentralbl Chir. 1999;124(5):428-35. German. PMID 10420530
- BACKGROUNDHeald RJ, Moran BJ, Ryall RD, Sexton R, MacFarlane JK. Rectal cancer: the Basingstoke experience of total mesorectal excision, 1978-1997. Arch Surg. 1998 Aug;133(8):894-9. doi: 10.1001/archsurg.133.8.894. PMID 9711965
- BACKGROUNDLaurent C, Nobili S, Rullier A, Vendrely V, Saric J, Rullier E. Efforts to improve local control in rectal cancer compromise survival by the potential morbidity of optimal mesorectal excision. J Am Coll Surg. 2006 Nov;203(5):684-91. doi: 10.1016/j.jamcollsurg.2006.07.021. Epub 2006 Sep 20. PMID 17084330
- BACKGROUNDKapiteijn E, Putter H, van de Velde CJ; Cooperative investigators of the Dutch ColoRectal Cancer Group. Impact of the introduction and training of total mesorectal excision on recurrence and survival in rectal cancer in The Netherlands. Br J Surg. 2002 Sep;89(9):1142-9. doi: 10.1046/j.1365-2168.2002.02196.x.